Doyle Jamie R, Harwood Benjamin N, Krishnaji Subrahmanian Tarakkad, Krishnamurthy Vijay M, Lin Wei-En, Fortin Jean-Philippe, Kumar Krishna, Kopin Alan S
Tufts Medical Center, Molecular Cardiology Research Institute, Molecular Pharmacology Research Center, Boston, Massachusetts, United States of America.
Tufts Medical Center, Molecular Cardiology Research Institute, Molecular Pharmacology Research Center, Boston, Massachusetts, United States of America; Program in Genetics, Sackler School of Graduate Biomedical Sciences, Tufts University, Boston, Massachusetts, United States of America.
PLoS One. 2014 Nov 12;9(11):e110502. doi: 10.1371/journal.pone.0110502. eCollection 2014.
Novel strategies are needed to expedite the generation and optimization of peptide probes targeting G protein-coupled receptors (GPCRs). We have previously shown that membrane tethered ligands (MTLs), recombinant proteins comprised of a membrane anchor, an extracellular linker, and a peptide ligand can be used to identify targeted receptor modulators. Although MTLs provide a useful tool to identify and/or modify functionally active peptides, a major limitation of this strategy is the reliance on recombinant protein expression. We now report the generation and pharmacological characterization of prototype peptide-linker-lipid conjugates, synthetic membrane anchored ligands (SMALs), which are designed as mimics of corresponding MTLs. In this study, we systematically compare the activity of selected peptides as MTLs versus SMALs. As prototypes, we focused on the precursor proteins of mature Substance P (SubP) and Cholecystokinin 4 (CCK4), specifically non-amidated SubP (SubP-COOH) and glycine extended CCK4 (CCK4-Gly-COOH). As low affinity soluble peptides these ligands each presented a challenging test case for assessment of MTL/SMAL technology. For each ligand, MTLs and corresponding SMALs showed agonist activity and comparable subtype selectivity. In addition, our results illustrate that membrane anchoring increases ligand potency. Furthermore, both MTL and SMAL induced signaling can be blocked by specific non-peptide antagonists suggesting that the anchored constructs may be orthosteric agonists. In conclusion, MTLs offer a streamlined approach for identifying low activity peptides which can be readily converted to higher potency SMALs. The ability to recapitulate MTL activity with SMALs extends the utility of anchored peptides as probes of GPCR function.
需要新的策略来加快针对G蛋白偶联受体(GPCR)的肽探针的生成和优化。我们之前已经表明,膜 tethered 配体(MTL),即由膜锚定物、细胞外连接子和肽配体组成的重组蛋白,可用于识别靶向受体调节剂。尽管MTL为识别和/或修饰功能活性肽提供了一种有用的工具,但该策略的一个主要局限性是依赖重组蛋白表达。我们现在报告了原型肽-连接子-脂质缀合物,即合成膜锚定配体(SMAL)的生成和药理学特征,其被设计为相应MTL的模拟物。在本研究中,我们系统地比较了选定肽作为MTL与SMAL的活性。作为原型,我们重点关注成熟P物质(SubP)和胆囊收缩素4(CCK4)的前体蛋白,特别是未酰胺化的SubP(SubP-COOH)和甘氨酸延伸的CCK4(CCK4-Gly-COOH)。作为低亲和力的可溶性肽,这些配体各自为评估MTL/SMAL技术提供了具有挑战性的测试案例。对于每种配体,MTL和相应的SMAL均显示出激动剂活性和相当的亚型选择性。此外,我们的结果表明膜锚定增加了配体的效力。此外,MTL和SMAL诱导的信号传导均可被特异性非肽拮抗剂阻断,这表明锚定构建体可能是正构激动剂。总之,MTL为识别低活性肽提供了一种简化的方法,这些低活性肽可以很容易地转化为高效力的SMAL。用SMAL重现MTL活性的能力扩展了锚定肽作为GPCR功能探针的效用。